Joseph C. Wu, MD, PhD, is Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu received his medical degree from Yale. He completed his medicine internship, residency, and cardiology fellowship (STAR program) at UCLA. He obtained his PhD in the Department of Molecular & Medical Pharmacology with Dr. Sam Sanjiv Gambhir. His clinical interests include adult congenital heart disease and cardiovascular imaging.
His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand cardiovascular disease mechanisms, (ii) accelerate drug discovery, (iii) develop "clinical trial in a dish" concept, and (iv) implement precision medicine for prevention and treatment of cardiovascular patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathological processes. Dr. Wu has published >500 manuscripts with H-index of 116 on Google scholar and recognition as top 1% of highly cited researchers in Web of Science for past 5 years (2018, 2019, 2020, 2021, 2022). Among his trainees, >45 of them are principal investigators in the US or abroad.
Dr. Wu has received numerous awards, including National Institutes of Health (NIH) Director’s New Innovator Award, NIH Roadmap Transformative Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama, American Heart Association (AHA) Innovative Research Award, AHA Established Investigator Award, AHA Merit Award, AHA Distinguished Scientist Award, and Burroughs Wellcome Foundation Innovation in Regulatory Science Award. Dr. Wu serves on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee and board of Keystone Symposia. He is co-founder of Greenstone Biosciences, a startup that uses clinical genomics, iPSCs, and AI/ML to accelerate drug discovery.
Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association of Physicians (AAP), American Association for the Advancement of Science (AAAS), Academia Sinica Taiwan, and National Academy of Medicine (NAM). Dr. Wu is also President-Elect of the American Heart Association.
Dr. Robert Harrington is Arthur L. Bloomfield Professor of Medicine and Chairman of the Department of Medicine at Stanford University. Dr. Harrington was previously the director of the Duke Clinical Research Institute (DCRI). His research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issue of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of clinical trials.
He has authored more than 400 peer-reviewed manuscripts, reviews, book chapters, and editorials. He is an associate editor of the American Heart Journal and an editorial board member for the JACC. He is a senior editor of the 13th edition of Hurst’s The Heart. He recently served as a member and the chair of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee.